Data from the nation’s initial set of patients receiving COVID-19 booster shots found similar rates and types of adverse reactions, such as pain at the injection site, headache or fatigue, according to a Centers for Disease Control and Prevention study released today. Within the study group, made up of 12,591 patients with moderate-to-severe immunocompromising conditions who reported on their conditions via CDC’s v-safe surveillance platform, adverse effects occurred with frequencies comparable to those from initial dosing regimens.

Related News Articles

Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…